Culver City, CA, United States of America

Bert Tsunyin Lai

This inventor holds 9 USPTO granted patents and 3 published patent applications and 3 EPO patents. Top assignees: Regeneron Pharmaceuticals, Inc., Indi Molecular, Inc., California Institute of Technology. Active years: 2020-2026.

USPTO Granted Patents = 9 (Patent Applications = 3)

% Patents Active = 88.9

EPO Patents = 3 (Patent Applications = 4)

Average Co-Inventor Count = 4.1

ph-index = 1

Forward Citations = 8(Granted Patents)

Location History:

Los Angeles, CA (US) (2023)
Culver City, CA (US) (2020 - 2024)

Company Filing History:

5 out of 1,479

Regeneron Pharmaceuticals, Inc.

California Institute of Technology

patents

where one patent can have more than one assignee

Years Active: 2020-2026

Loading Chart...

9 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12594350 - CD8-SPECIFIC CAPTURE AGENTS, COMPOSITIONS, AND METHODS OF USING AND MAKING (2026-04-07),

2. 12546785 - IL-17F AND IL-17A-SPECIFIC CAPTURE AGENTS, COMPOSITIONS, AND METHODS OF USING AND MAKING (2026-02-10),

3. 12517136 - IL-17F-SPECIFIC CAPTURE AGENTS, COMPOSITIONS, AND METHODS OF USING AND MAKING (2026-01-06),

4. 12216122 - Compositions and methods relating to detection, inhibition, and imaging of indoleamine 2,3-dioxygenase 1 (IDO1) (2025-02-04),

5. 11884707 - Compositions for detection, inhibition and imaging of indoleamine 2, 3-dioxygenase 1 (IDO1) and methods of making and using same (2024-01-30),

6. 11766414 - Compositions, delivery systems, and methods useful in tumor therapy (2023-09-26),

7. 11733246 - Compositions, imaging, and therapeutic methods targeting folate receptor 1 (FOLR1) (2023-08-22),

8. 11719705 - IL-17F and IL-17A-specific capture agents, compositions, and methods of using and making (2023-08-08),

9. 10598671 - IL-17F-specific capture agents, compositions, and methods of using and making (2020-03-24),

Title: Bert Tsunyin Lai: Innovator in Biochemical Detection and Therapeutics

Introduction

Bert Tsunyin Lai is a notable inventor based in Culver City, CA (US). He has made significant contributions to the field of biochemical detection and therapeutics, holding a total of 9 patents. His work focuses on innovative methods and compositions that enhance the detection and inhibition of specific biochemical agents.

Latest Patents

Among his latest patents is the development of IL-17F-specific capture agents, compositions, and methods of using and making them. This patent includes compositions and methods related to the detection, inhibition, and imaging of indoleamine 2,3-dioxygenase 1 (IDO1). The application provides stable heterobiligands composed of peptide-based IDO1 ligands and small molecule inhibitors of IDO1. Furthermore, it outlines methods for using these heterobiligands as detection, imaging, diagnostic, and therapeutic agents, as well as methods for manufacturing IDO1 heterobiligands, capture agents, and imaging agents.

Career Highlights

Bert has worked with prominent companies in the biotechnology sector, including Indi Molecular, Inc. and Regeneron Pharmaceuticals, Inc. His experience in these organizations has allowed him to develop and refine his innovative approaches to biochemical research and applications.

Collaborations

Throughout his career, Bert has collaborated with talented professionals, including Heather Dawn Agnew and Anders Eliasen. These collaborations have contributed to the advancement of his research and the successful development of his patented technologies.

Conclusion

Bert Tsunyin Lai is a distinguished inventor whose work in biochemical detection and therapeutics has led to significant advancements in the field. His innovative patents and collaborations reflect his commitment to enhancing scientific understanding and application in biochemistry.